Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.

Stock Quote Today & Recent News NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Our first product ExoPTEN for acute spinal cord injury has been granted Orphan Drug Designation by the FDA.

Dr. Lior Shaltiel

Current News (TSXV:NRX)

NurExone's ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

GlobeNewswire 2 days ago

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

GlobeNewswire 9 days ago

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

GlobeNewswire June 11, 2024

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

GlobeNewswire June 4, 2024

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

GlobeNewswire May 29, 2024

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

GlobeNewswire May 17, 2024
View More News ››

We are developing a unique and futuristic drug delivery system—exosomes deliver therapeutic cargo to tissues and organs, promoting a healing environment for neuroregeneration.

Dr. Lior Shaltiel

Opinion & Analysis (TSXV:NRX)

ExoTherapy offers hope for treating acute spinal cord injuries

Brieanna McCutcheon  September 19, 2023
View More Opinion ››

Bullboard Posts (TSXV:NRX)

Nurexone Accelerates Growth with Dr. Yona Geffen’s Expertise

NurExone Biologic Inc. Accelerates Growth with Dr. Yona Geffen’s Expertise (TSXV: NRX, OTCQB: NRXBF) ...
Mathew177 - 3 days ago

NurExone Biologic Inc - LitchField Hills Research Report

NurExone Biologic Inc - LitchField Hills Research Report (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V) ...
ElliotGH - June 6, 2024

$NRX Game-Changing Moves in Biopharmaceuticals and Exosome

NurExone’s Game-Changing Moves in Biopharmaceuticals and Exosome Technology (TSXV: NRX, OTCQB: NRXBF...
Mathew177 - June 4, 2024

NurExone's Expands Commercialization Efforts with All-star H

https://10xalerts.com/nurexones-expands-commercialization-efforts-with-all-star-hire-tsxv-nrx/
Brice978 - May 24, 2024

2.5 years to break even for this company

thats a long wait for a maybe....this one is for patient speculators only.....no quick trade flip here....go try those meme stocks for a...
88guy88 - May 14, 2024

Wait for 41 cents

looks like it wants to head back to the 200 day moving average which is 41 cents....no news or results for a long time while they do...
88guy88 - May 13, 2024
View more Bullboard ››

Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube

PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu